Latest Commercialization News

National Australia Bank reported a modest rise in underlying profit for FY25, driven by robust revenue and volume growth in the second half, alongside continued technology modernization and sustainability progress.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

Eagle Mountain Mining has received a non-binding indicative offer from Japan’s Nittetsu Mining to form a joint venture, injecting up to US$20 million to advance the Oracle Ridge copper project towards production by 2030.

Eagle Mountain Mining has secured a 12-month exclusive option to acquire the Oracle Ridge copper mine’s surface and mineral rights, positioning the company to potentially restart production on a resource containing 380,000 tons of copper.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Melbana Energy’s latest drilling at Amistad-2 in Cuba reveals excellent reservoir quality but disappointingly no oil production, prompting a strategic pivot in exploration plans.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

RAS Technology Holdings has landed a significant contract to provide racing data and managed trading services for LeoVegas Group’s UK brands, including BetMGM UK, marking a strategic expansion into regulated markets.

FBR Limited has inked a non-binding Memorandum of Understanding with Fraser Lyne Constructions for the sale of a Hadrian® bricklaying robot unit valued at A$7.8 million, aiming to tackle New South Wales' housing shortage with advanced automation.

BPH Global has locked in a six-month exclusive agreement to evaluate a proprietary ginseng-based formulation aimed at enhancing male vitality, signaling a strategic push into Traditional Chinese Medicine-inspired wellness products.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.